GLP1 analogs: Blazing new trails in diabetes management
PDF (Español (España))
xhtml (Español (España))



How to Cite

Casas Figueroa, L. A. (2022). GLP1 analogs: Blazing new trails in diabetes management. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 9(2).


In the early 1900s (1902), researchers Bayliss and Starling described that pancreatic secretions were produced by chemical stimuli as well as neural stimuli, and that secretions coming from the intestine contained "something" that was released into the circulation and had the ability to stimulate pancreatic secretions, the first hormone being named secretin. These findings contributed to the understanding that there are key interactions between hormones and the nervous system, which are necessary for gastrointestinal functions. A few years later these hormones were considered to contribute to glucose regulation in diabetic patients, supported by Barre's experiments, and the effect of incretin, given by gastrointestinal hormones after oral glucose loading, was later clarified by research published by Perley and Kipnis. In 1983 a glucagon-like peptide (GLP-1) was isolated from the intestine and found to stimulate insulin secretion and inhibit glucagon secretion, as well as inhibitory effects on food intake and gastric emptying, which prompted the development of GLP-1-based treatments.
PDF (Español (España))
xhtml (Español (España))


Bayliss WM, Starling EH. The mechanism of pancreatic secretion. J Physiol. 1902 sept. 12;28(5):325-53.

Zuns E, La Barre J. Contributions a l’étude des variations physiologiques de la sécrétion interne du pancréas relations entre les sécrétions externe et interne du pancréas. Arch Intern Physiol. 1929;31:20-44.

Perley J, Kipnis DM. Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects. J. Clin Invest. 1967 dic.;46(12):1954-62.

Bell GI, Santerre DF, Mullenbach GT. Hamster preproglucagon contains sequence of glucagon and two related peptides. Nature. 1983;302:716-8.

Drucker DJ, Habener JF, Juul-Holst J. Discovery, characterization, and clinical development of the glucagon-like peptides. J. Clin Invest. 2017;127(12):4217-27.

Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino M, Bellastella G, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20(1):189.

Zhuo C, Lin C, Zhou C, Gao X, Shao H, Fang T, et al. Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analisis. Front Pharmacol. 2021;12.

Hurtado-Amézquita YC, Acosta-Ospina MF, Valenzuela A, Omeara M, Lizcano F. Uso de medicación con efecto incretina para control glucémico en pacientes adultos hospitalizados con diabetes mellitus tipo 2 entre 2002 y 2018. Rev Colomb Endocrinol Diabet Metab. 2022;9(2).

Cantor-Cruz F, Gómez-Gómez O, Mendivelso-Duarte F, Ruiz PC, Rincón-Sierra O, Yama-Mosquera E, et al. GLP-1RA en el manejo de diabetes mellitus tipo 2: una validación de revisiones sistemáticas. Rev Colomb Endocrinol Diabet Metab. 2022;9(2).

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2022 Revista Colombiana de Endocrinología, Diabetes & Metabolismo




Download data is not yet available.